M Fox1, M Thumshirn, D Menne, B Stutz, M Fried, W Schwizer. 1. Department of Gastroenterology and Hepatology, University Hospital of Zürich, Zürich, Switzerland Menne Biomed, Tübingen, Germany.
Abstract
BACKGROUND: The intermittent loss of oil or liquid faeces ('spotting') is an adverse effect that occurs in obese patients during treatment with thelipase inhibitor orlistat; the pathophysiology is unknown. AIM: To investigate the effects of orlistat on anorectal sensorimotor function and continence. METHODS:Obese subjects susceptible to spotting were identified by an unblind trial of orlistat. Obese spotters (n = 15) and non-spotters (n = 16) completed a randomized, double-blind, cross-over trial of orlistat and placebo. Anorectal function was assessed by rectal barostat and anal manometry, together with a novel stool substitute retention test, a quantitative measurement of faecal continence. RESULTS:Orlistat increased stool volume and raised faecal fat and water. Treatment had no effect on anorectal motor function, but rectal sensation was reduced; on retention testing, the volume retained was increased. Subjects susceptible to spotting had lower rectal compliance, heightened rectal sensitivity and weaker resting sphincter pressure than non-spotters. On retention testing, gross continence was maintained; however, spotters lost small volumes of rectal contents during rectal filling. CONCLUSION: Treatment with orlistat has no direct adverse effects on anorectal function or continence. Spotting occurs during treatment with orlistat when patients with sub-clinical anorectal dysfunction are exposed to increased stool volume and altered stool composition.
RCT Entities:
BACKGROUND: The intermittent loss of oil or liquid faeces ('spotting') is an adverse effect that occurs in obesepatients during treatment with the lipase inhibitor orlistat; the pathophysiology is unknown. AIM: To investigate the effects of orlistat on anorectal sensorimotor function and continence. METHODS:Obese subjects susceptible to spotting were identified by an unblind trial of orlistat. Obese spotters (n = 15) and non-spotters (n = 16) completed a randomized, double-blind, cross-over trial of orlistat and placebo. Anorectal function was assessed by rectal barostat and anal manometry, together with a novel stool substitute retention test, a quantitative measurement of faecal continence. RESULTS: Orlistat increased stool volume and raised faecal fat and water. Treatment had no effect on anorectal motor function, but rectal sensation was reduced; on retention testing, the volume retained was increased. Subjects susceptible to spotting had lower rectal compliance, heightened rectal sensitivity and weaker resting sphincter pressure than non-spotters. On retention testing, gross continence was maintained; however, spotters lost small volumes of rectal contents during rectal filling. CONCLUSION: Treatment with orlistat has no direct adverse effects on anorectal function or continence. Spotting occurs during treatment with orlistat when patients with sub-clinical anorectal dysfunction are exposed to increased stool volume and altered stool composition.
Authors: Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf Journal: Drug Saf Date: 2008 Impact factor: 5.606
Authors: Isaac José Felippe Corrêa Neto; Rodrigo Ambar Pinto; José Marcio Neves Jorge; Marco Aurélio Santo; Leonardo Alfonso Bustamante-Lopez; Ivan Cecconello; Sérgio Carlos Nahas Journal: Obes Surg Date: 2017-07 Impact factor: 4.129
Authors: Dean Gilham; Eric D Labonté; Juan C Rojas; Ronald J Jandacek; Philip N Howles; David Y Hui Journal: J Biol Chem Date: 2007-06-29 Impact factor: 5.157